© The Author(s) 2023. www.omniscient.sg © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Advanced Materials Science and Technology Vol 5 Issue 2 2023 DOI: 10.37155/2717-526X-0502-2 ORIGINAL RESEARCH ARTICLE Open Access Tailored Non-ionic Surfactant Vesicles of Cyclosporine for the Treatment of Psoriasis: Formulation, Ex-Vivo and In-Vivo Investigation-Application of Box-Behnken Design Peeyush Bhardwaj 1 , Purnima Tripathi 2* , Sonia Pandey 3 , Deepti Chaurasia 4 and Purushottam Ramchandra Patil 5 1 Department of Pharmacy, Bundelkhand University, Jhansi, U.P. 284128, India. 2 B.S. Anangpuria Institute of Pharmacy, Alampur, Ballabgarh - Sohna Major District Road, Faridabad, 121004, Haryana, India. 3 Faculty of Pharmaceutical Sciences, Rama University, Mandhana, Kanpur, U.P. 209217, India. 4 Nkbr College of Pharmacy And Research Centre, Meerut, U.P. 245206, India. 5 Government College of Pharmacy, Osmanpura, Aurangabad, Maharashtra, India. *Correspondence to: Purnima Tripathi, B.S. Anangpuria Institute of Pharmacy, Alampur, Ballabgarh - Sohna Major District Road, Faridabad, 121004, Haryana, India. Email: Tripathi.purnima@gmail.com Received: August 15, 2023; Accepted: November 20, 2023; Published Online: November 30, 2023 Citation: Bhardwaj P, Tripathi P, Pandey S, Chaurasia D and Ramchandra Patil P. Tailored Non-ionic Surfactant Vesicles of Cyclosporine for the Treatment of Psoriasis: Formulation, Ex-Vivo and In-Vivo Investigation- Application of Box-Behnken Design. Advanced Materials Science and Technology, 2023;5(2):0520492. https://doi.org/10.37155/2717-526X-0502-2 Abstract: Psoriasis is an autoimmune skin disease characterized by hyperproliferation of keratinocytes. Topical delivery of drugs is mostly favored for the treatment of mild psoriatic conditions. But permeation of drugs across psoriatic skin is too complex. Niosomes are the non-ionic surfactant vesicles, reported to enhance dermal drug delivery. In the present work, cyclosporine niosomes were, formulated, optimized, and evaluated in-vitro to boost the dermal penetration of cyclosporine for the better management of psoriasis. Niosomes were developed using the thin film hydration method. Formulated niosomes were characterized and optimized for their percent encapsulation efficiency, size, and polydispersity index using Box-Behnken design. Optimized formulation was developed using cholesterol and span 60 (1:2.2), 30 minutes of hydration time, and 30 mg of cyclosporine. Niosomes’ size, polydispersity index, and percent encapsulation efficiency were in the scale of 180.5 ± 11.16 nm, 0.156, and 93.2% ± 2.5%, respectively. The ex-vivo studies were carried out using excised goat skin. In the ex-vivo permeation experiments, though the percent drug permeated was low but the quantity